Background: Preeclampsia is a serious pregnancy complication characterized by endothelial dysfunction, leading to symptoms like proteinuria and hypertension. Several other symptoms, including edema, hemostasis disruption, renal or hepatic failure, and the HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet counts), depending on the systemic involvement. According to recent data, endothelial dysfunction in preeclampsia may be caused by an antiangiogenic state that is mediated by low levels of proangiogenic factors such as vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in combination with high levels of soluble endoglin (sEng) and circulating soluble Fms-like tyrosine kinase 1 (sFlt1). The release of sFlt1 and sEng from the placenta into the mother's blood contributes to endothelial dysfunction in preeclampsia. High levels of sFlt1 have been linked to the severity of preeclampsia, suggesting a potential biomarker for the condition. Variants near the FLT1 gene in the fetal genome have been associated with an increased risk of preeclampsia, highlighting a genetic component to the disorder. Objective: This article aimed to throw the light onpreeclampsia as a risk factor in diabetic pregnancies, management and therapies challenges Material and methods: We searched Google Scholar, Science Direct, PubMed and other online databases for Preeclampsia, Pregnancy, Gestational hypertension, sFlt1. The authors also reviewed references from pertinent literature, however only the most recent or comprehensive studies from 1985 to 2023 were included. Documents in languages other than English were disqualified due to lack of translation-related sources. Papers such as unpublished manuscripts, oral presentations, conference abstracts, and dissertations that were not part of larger scientific studies were excluded. Conclusion: The identification of specific risk cohorts for preeclampsia utilizing easily accessible and efficient technologies, particularly in low-resource settings, has the potential to yield improved public health outcomes for both mothers and newborns by enabling the initiation of prenatal interventions before the onset of complications. In pursuit of this objective, there has been a growing interest in exploring technologies to enhance the overall comprehension of preeclampsia and, more specifically, its predictive capabilities. These technological advancements promise to advance our understanding of preeclampsia and improve our ability to anticipate and mitigate its adverse effects.